Fibrocell Science (OTC:FCSC) - smoothing out wrinkles with cells of your own

Company:  Fibrocell Science, Inc. (OTC: FCSC)

Catalyst:  PDUFA 2011-06-22

Product candidate:  azficel-T (Laviv TM)

Indication:  Nasolabial fold wrinkles

Recent news:

Jan. 12, 2011

The U.S. Food & Drug Administration (FDA) has accepted for review the Company’s complete response submission for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles. The Prescription Drug User Fee Act (PDUFA) date is June 22, 2011 (read full press release).

Feb. 15, 2011

Fibrocell completed $7.8 million of capital raise.  The company's stock was diluted, offering 2,960,000 shares of Company common stock at an exercise price of $0.50 per share (read full press release). 

Recent trend:  + 49% in a month

Current price:  $0.895

Price target:  low to mid $1 range

About azficel-T

Fibroblasts are cells that contribute to the formation of connective tissue fibers, and regenerative fibroblast cells may have potential in use for broad aesthetic, medical and scientific applications.

Fibrocell Science’s lead therapy, azficel-T, is an investigational autologous (personalized) cell therapy. In the Fibrocell Science patented process, a patient's own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy to regenerate skin. Azficel-T is currently under review by the U.S. Food & Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles. Also, the Company recently submitted a clinical study report to the FDA for a Phase II/III trial of azficel-T in acne scarring.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.